Amylyx Pharmaceuticals (AMLX) Q3 2026 earnings review
Amylyx's blood sugar drug worked, and investors funded its launch
Amylyx's one decisive experiment worked, and the drug developer then sold shares to pay for a launch. Its late-stage trial of avexitide cut dangerous blood-sugar drops by 55% against a placebo. Co-chief executive Justin Klee said Amylyx will file for approval by the end of December. Costs are climbing well before any sales: operating spending reached $49.7 million, 38% above a year ago.
| Net loss | $45.5 million $34.4 million a year ago |
|---|---|
| Total operating costs | $49.7 million +38% from a year ago |
| Cash, deposits and bonds | $768.1 million $250.8 million three months earlier |
| Funding outlook | Broadened now covers a possible launch; earlier wording said into 2028 |
⚖️ Verdict: 🟢 Bullish
The case got better, because the one result the whole business depended on came in positive and the money to act on it arrived weeks later. One caution: the decisive study enrolled only gastric bypass patients, so the first label may not cover the market Amylyx describes. Costs are also rising.
The question now is how wide a label the FDA will grant. One answer: it covers the condition itself, because the biology works the same way after any weight-loss operation. The other: it names gastric bypass, which Amylyx puts at about 120,000 of the 160,000 Americans it counts. Next year's review settles it.
🐂 Bull Case
Avexitide Cut Dangerous Blood Sugar Drops 55%
Everything at Amylyx rested on one trial. LUCIDITY tested avexitide, a daily injection that blocks the hormone GLP-1, in 78 people whose blood sugar falls to dangerous levels after gastric bypass surgery. Two of every five participants received a placebo instead, and the treatment period ran 16 weeks.
The drug cut the combined rate of the two most severe kinds of low-blood-sugar episode by 55% against placebo, with a p-value of 0.000003, and it met every secondary measure as well. Chief medical officer Camille Bedrosian said this was the sixth avexitide trial in the condition and that all six produced statistically significant results.
That outcome removes the one event that could have ended the business, and it rests on episodes patients notice rather than on an average reading. More than nine in ten participants finished the double-blind period, which weakens the old worry that people drift from their diets and blur the comparison.
What to watch: the full data set at ObesityWeek on November 15, and especially how many patients stopped having severe episodes altogether. A high share would give Amylyx its strongest argument when it talks price with insurers next year.
Amylyx Raised $545 Million for the Launch
Three months ago Amylyx held $250.8 million and faced a launch it could not pay for. Days after the trial result, it sold stock at $35.50 a share and collected $544.6 million after fees. Cash, deposits and bonds stood at $768.1 million on September 30.
Finance chief Jim Frates called the sale an "oversubscribed equity offering" and said it drew "anchor orders from a number of leading experienced investors". The money pays for what a launch needs: a field force, two manufacturers and a cushion, with no return trip to the market in between. Shareholders funded that in ownership.
What to watch: whether Amylyx sells stock again before approval arrives. It says the cash covers the planned launch, so a further offering during 2027 would tell investors that launch costs ran past what the plan assumed.
The Commercial Team Is Now Fully Hired
A first-of-its-kind drug needs someone to sell it. Chief commercial officer Dan Monahan said Amylyx has moved "from launch planning to executing on our launch readiness roadmap", with its full commercial leadership team in place and further hires in marketing, insurance access, patient services and operations.
Two outside developments helped. A diagnosis code for this condition took effect in October, so doctors and insurers can finally count these patients, though Monahan warned that a new code "is going to take some time to be absorbed across the broader medical community". Endocrinologists will write most prescriptions, he said, and some practices follow more than 100 such patients.
What to watch: how many sales representatives Amylyx hires, a number nobody has published yet. The size of that field force will show how broadly the team expects to sell in the first year after approval.
🐻 Bear Case
The Trial Covered Only Bypass Patients
Amylyx counts about 160,000 Americans with this condition. Its decisive trial enrolled only people whose low blood sugar followed Roux-en-Y gastric bypass, one of the two common weight-loss operations. Klee puts that group at roughly 120,000, which leaves the remainder outside the evidence the application leans on.
- Gastric bypass patients with the condition: about 118,000, on Amylyx's claims work
- Sleeve gastrectomy patients with the condition: about 48,000
- LUCIDITY participants: 78, all of them gastric bypass
- Earlier mid-stage trial covering other upper-gut surgeries: results also positive
Bedrosian said the submission will carry the whole avexitide programme, including that mid-stage study, and added that it is "too early yet to be contemplating what the label or the indication will be". Klee argues "the pathophysiology is the same" whatever the operation. Insurers, though, pay against the label rather than the biology.
What to watch: the wording the FDA grants during next year's review. A label naming the condition rather than the operation would open the sleeve gastrectomy group without a further trial, and a narrower one would push that work into 2028.
Costs Rose 38% With No Product Revenue
Amylyx sells nothing, so every dollar it spends comes from investors, and the bill keeps getting bigger. Operating costs reached $49.7 million in the quarter, 38% more than a year earlier. The net loss widened to $45.5 million. Nine months of operations consumed $102.0 million of cash.
- Research and development: $28.4 million, up 43%
- Avexitide programme alone: $10.7 million, against $4.9 million a year ago
- Selling and administrative: $21.3 million, up 32%
- Closed brain-disease programme: a $0.4 million credit, against $3.0 million of spending a year ago
Amylyx gives two reasons for the administrative step-up: more staff for pre-launch work, and more consulting as marketing begins. The discontinued trial in a rare brain disorder held the total down, because winding it up released money rather than using it. Nothing offsets the increase that way next year.
What to watch: cash use in the fourth quarter, reported in February, and whether the filing again names the year the money runs to. By our math the business used about $27 million of cash this quarter, far less than its reported loss, because share-based pay and interest income sit between the two.
Risks this quarter didn't answer
Five standing worries got words this quarter but no numbers. Executives answered a question on each of them, and in every case the figure that would settle the argument arrives in a later period.
- Weight-loss drugs: Josh Cohen cited three randomized trials finding no benefit from GLP-1 agonists against this kind of low blood sugar; whether those drugs cut future bariatric surgery volumes went unanswered.
- Price: Monahan said the pricing work starts now and pointed to rare hormone-disease products with similar patient numbers; no figure yet.
- Insurance: national account directors are on board, with payer meetings set for the first quarter of 2027; no coverage terms yet.
- Undiagnosed patients: four rounds of claims analysis keep producing the same market size, but the new diagnosis code will spread slowly.
- Wolfram syndrome: the release never mentions the planned late-stage trial, and the quarterly filing says only that work with the FDA continues.
👓 Other Themes
Amylyx Lined Up Two Drug Manufacturers
In September, Amylyx signed a five-year commercial supply agreement with Bachem for avexitide and a term sheet with Polypeptide that carries a $30 million fee up front to reserve capacity. Neither supplier holds exclusivity. From 2028 the buyer must take a minimum quantity each year, so fixed obligations now start before the first prescription.
A Second GLP-1 Blocker Heads for the Clinic
Avexitide needs an injection every day. AMX0318 blocks the same hormone for longer, and the animal and laboratory work required before human testing is under way; Cohen called it "progressing well" and pointed to a 2027 application. A second research deal with the Danish peptide firm Gubra, signed in July, targets another rare hormone disease.
💲 Other KPIs
Amylyx pays for itself by selling shares, and the count keeps climbing: the quarterly average reached 118.9 million, 27% above a year ago. August's sale added 16.2 million shares. By September 30 the register held 128.5 million shares, with option exercises adding to the total each quarter.
Pay in shares now takes a fifth of the cost base, its highest share in two years. The charge rose 47% from a year ago, lifted by $1.7 million for a performance award that vested when the trial result landed. None of it leaves the bank, which is why the loss looks bigger than the cash use.
Money owed to outside labs and factories for work already done more than doubled since December, to $11.0 million. Such bills usually run ahead of the spending they belong to, so the line points to further research and manufacturing cost in the fourth quarter and the first of next year.
🔮 Guidance
New. Amylyx will show the full LUCIDITY results in a late-breaking talk in Washington. August gave investors one headline figure and a p-value; this meeting is where the secondary measures, the safety detail and the spread between treated and untreated patients become visible. Doctors decide what to prescribe on that detail.
Unchanged, and now dated. The company says the submission is on track for the end of December, and Klee repeated that the team is "on track to submit our NDA to the FDA by the end of this year". Avexitide holds breakthrough and orphan status, so the agency has been working alongside Amylyx before the filing arrives.
Unchanged, for the ninth quarter running. Amylyx still aims to sell avexitide during 2027 if regulators clear it, and has not narrowed the date within the year. The review clock only starts when the application goes in, so December's filing sets how early in 2027 a launch can begin.
Unchanged for a fourth quarter. The studies needed before human testing continue, and Cohen described them as "progressing well". This one does not touch the launch, but a longer-acting blocker would eventually spare patients a daily injection, which is why the date matters for the years after 2027.
Raised. Amylyx now says its money funds the planned work, a launch included. At this quarter's cash use of about $27 million, by our math that is roughly seven years, though hiring a sales force will cut the figure sharply. One change deserves attention: the filing no longer names 2028, the year it cited for four straight quarters.
❓ Key Questions
What will quarterly spending be during the launch?
Amylyx dropped the year its cash lasts to and is hiring a field force. A planned spending rate for 2027 would let investors judge how long $768 million really lasts.
How many patients stopped having severe episodes?
Management left the distribution of results to the November 15 talk. The share of patients who became event-free decides how strong the pricing argument with insurers will be.
How many patients are in the early access programme?
Cohen declined to give interim numbers. The count, and the split between trial veterans and new patients, shows how quickly real-world demand appears once prescribing opens.
What price analogues sit behind the plan?
Monahan pointed to rare hormone-disease products with similar patient numbers but named none. Without a price range, no revenue estimate for 2027 can be more than a guess.
When does the Wolfram syndrome trial start?
The start moved from the second half of 2026 to the first half of 2027, and this quarter's release does not mention it. The filing says only that work with the FDA continues.